Marianne Gerber
Roche (Switzerland)(CH)
Publications by Year
Research Areas
Neurogenetic and Muscular Disorders Research, RNA modifications and cancer, RNA Research and Splicing, RNA and protein synthesis mechanisms, Neonatal Respiratory Health Research
Most-Cited Works
- → Progressive multifocal leukoencephalopathy: current treatment options and future perspectives(2015)211 cited
- → Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial(2021)209 cited
- → Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo‐controlled, dose‐finding trial followed by 24 months of treatment(2022)61 cited
- → Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy(2020)35 cited
- → SUNFISH Part 2: Efficacy and Safety of Risdiplam (RG7916) in Patients with Type 2 or Non-Ambulant Type 3 Spinal Muscular Atrophy (SMA) (1260)(2020)30 cited
- → FIREFISH Part 2: Efficacy and Safety of Risdiplam (RG7916) in Infants with Type 1 Spinal Muscular Atrophy (SMA) (1302)(2020)25 cited
- → RAINBOWFISH: A Study of Risdiplam in Newborns with Presymptomatic Spinal Muscular Atrophy (SMA) (4281)(2021)16 cited
- → Update from SUNFISH Part 1: Safety, Tolerability and PK/PD from the Dose-Finding Study, Including Exploratory Efficacy Data in Patients with Type 2 or 3 Spinal Muscular Atrophy (SMA) Treated with Risdiplam (RG7916) (S25.007)(2019)11 cited
- → FIREFISH Part 1: 1-Year Results on Motor Function in Babies with Type 1 SMA (S25.003)(2019)11 cited
- → RAINBOWFISH: Preliminary Efficacy and Safety Data in Risdiplam-Treated Infants with Presymptomatic SMA (P17-5.003)(2022)10 cited